{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T01:54:23Z","timestamp":1785549263005,"version":"3.56.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T00:00:00Z","timestamp":1653609600000},"content-version":"vor","delay-in-days":2644,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","fertstert.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Fertility and Sterility"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.fertnstert.2015.01.019","type":"journal-article","created":{"date-parts":[[2015,2,26]],"date-time":"2015-02-26T20:01:44Z","timestamp":1424980904000},"page":"605-611","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Off-label drug use in the treatment of\u00a0polycystic ovary syndrome"],"prefix":"10.1016","volume":"103","author":[{"given":"Wendy","family":"Vitek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Snigdha","family":"Alur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M.","family":"Hoeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.fertnstert.2015.01.019_bib1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/humrep\/deh098","article-title":"Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)","volume":"19","year":"2004","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2015.01.019_bib2","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1093\/humrep\/des463","article-title":"Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp","volume":"28","author":"Stepto","year":"2013","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2015.01.019_bib3","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/j.1365-4632.2007.03270.x","article-title":"The effect of eflornithine 13.9% cream on the bother and dicomfort due to hirsutism","volume":"46","author":"Jackson","year":"2007","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.fertnstert.2015.01.019_bib4","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000315499","article-title":"Best practice options for hair removal in patients with unwanted facial hair using combination therapy with laser: guidelines drawn up by an expert working gorup","volume":"221","author":"Lapidoth","year":"2010","journal-title":"Dermatology"},{"key":"10.1016\/j.fertnstert.2015.01.019_bib5","first-page":"343","article-title":"Risk of venous thromboembolism form use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001\u20139","author":"Lidegaard","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.fertnstert.2015.01.019_bib6","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2337\/dc06-0618","article-title":"Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome","volume":"30","author":"Meyer","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.fertnstert.2015.01.019_bib7","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1210\/jc.2004-1843","article-title":"Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study","volume":"90","author":"Legro","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.fertnstert.2015.01.019_bib8","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1055\/s-0032-1328878","article-title":"Obesity and PCOS: implications for diagnosis and treatment","volume":"30","author":"Legro","year":"2012","journal-title":"Semin Reprod Med"},{"key":"10.1016\/j.fertnstert.2015.01.019_bib9","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1093\/humrep\/dem108","article-title":"Quality of life and psychological well being in polycystic ovary syndrome","volume":"22","author":"Barnard","year":"2007","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2015.01.019_bib10","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.physbeh.2009.05.020","article-title":"Hyperandrogenemia, psychological distress, and food cravings in young women","volume":"98","author":"Lim","year":"2009","journal-title":"Physiol Behav"},{"key":"10.1016\/j.fertnstert.2015.01.019_bib11","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1056\/NEJM199806253382603","article-title":"Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome","volume":"338","author":"Nestler","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fertnstert.2015.01.019_bib12","first-page":"CD003053","article-title":"Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, d-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility","author":"Tang","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.fertnstert.2015.01.019_bib13","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1056\/NEJMoa063971","article-title":"Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome","volume":"356","author":"Legro","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fertnstert.2015.01.019_bib14","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1093\/humrep\/dem005","article-title":"Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review","volume":"22","author":"Costello","year":"2007","journal-title":"Hum Reprod"},{"key":"10.1016\/j.fertnstert.2015.01.019_bib15","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1210\/jc.2013-2350","article-title":"Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline","volume":"98","author":"Legro","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.fertnstert.2015.01.019_bib16","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.5694\/mja11.10915","article-title":"Assessment and management of polycystic ovary syndrome: summary of an evidence-based guideline","volume":"195","author":"Teede","year":"2011","journal-title":"Med J Aust"},{"key":"10.1016\/j.fertnstert.2015.01.019_bib17","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1210\/jc.2011-3061","article-title":"Metformin improves pregnancy and live-birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double-blind, placebo-controlled randomized trial","volume":"97","author":"Morin-Papunen","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.fertnstert.2015.01.019_bib18","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1111\/aogs.12015","article-title":"On the potential of metformin to prevent preterm delivery in women with polycystic ovary syndrome\u2014an epi-analysis","volume":"91","author":"Vanky","year":"2012","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.fertnstert.2015.01.019_bib19","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fertnstert.2015.01.019_bib20","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1056\/NEJM199904293401703","article-title":"Ovulatory and metabolic effects of d-chiro-inositol in the polycystic ovary syndrome","volume":"340","author":"Nestler","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fertnstert.2015.01.019_bib21","first-page":"151","article-title":"Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo-controlled trial","volume":"7","author":"Gerli","year":"2003","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.fertnstert.2015.01.019_bib22","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1586\/17512433.2014.925795","article-title":"Updates on the myo-inositol plus d-chiro-inositol combined therapy in polycystic ovary syndrome","volume":"7","author":"Unfer","year":"2014","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.fertnstert.2015.01.019_bib23","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.fertnstert.2004.02.127","article-title":"Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity","volume":"82","author":"Baillargeon","year":"2004","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2015.01.019_bib24","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1530\/eje.1.02331","article-title":"Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: a randomized placebo-controlled study","volume":"156","author":"Majuri","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.fertnstert.2015.01.019_bib25","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1210\/jc.2010-2547","article-title":"Drospirenone\/ethinyl estradiol versus rosiglitazone treatment in overweight adolescents with polycystic ovary syndrome: comparison of metabolic, hormonal, and cardiovascular risk factors","volume":"96","author":"Tfayli","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.fertnstert.2015.01.019_bib26","first-page":"347","article-title":"Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS","volume":"11","author":"Gerli","year":"2007","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.fertnstert.2015.01.019_bib27","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/cen.12468","article-title":"Fasting and post-prandial glucagon like peptide 1 and oral contraception in polycystic ovary syndrome","volume":"81","author":"Aydin","year":"2014","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.fertnstert.2015.01.019_bib28","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1530\/EJE-08-0097","article-title":"Incretin levels in polycystic ovary syndrome","volume":"159","author":"Vrbikova","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.fertnstert.2015.01.019_bib29","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1210\/jc.2008-0115","article-title":"Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome","volume":"93","author":"Elkind-Hirsch","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.fertnstert.2015.01.019_bib30","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1530\/EJE-13-0797","article-title":"Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin","volume":"170","author":"Jensterle Sever","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.fertnstert.2015.01.019_bib31","first-page":"140","article-title":"The effect of liraglutide on weight loss in women with polycystic ovary syndrome: an observational study","volume":"27","author":"Rasmussen","year":"2014","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.fertnstert.2015.01.019_bib32","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2337\/dc08-1355","article-title":"Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (Liraglutide Effect and Action in Diabetes)\u20132 study","volume":"32","author":"Nauck","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.fertnstert.2015.01.019_bib33","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(08)61246-5","article-title":"Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial","volume":"373","author":"Garber","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.fertnstert.2015.01.019_bib34","first-page":"1","article-title":"Short-term intervention with liraglutide improved eating behavior in obese women with polycystic ovary syndrome","volume":"20","author":"Jensterle","year":"2014","journal-title":"Endocr Res"},{"key":"10.1016\/j.fertnstert.2015.01.019_bib35","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1210\/jc.2010-0770","article-title":"Statins inhibit growth of human theca-interstitial cells in PCOS and non-PCOS tissues independently of cholesterol availability","volume":"95","author":"Sokalska","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.fertnstert.2015.01.019_bib36","first-page":"CD008565","article-title":"Statins for women with polycystic ovary syndrome not actively trying to conceive","author":"Raval","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.fertnstert.2015.01.019_bib37","doi-asserted-by":"crossref","first-page":"4798","DOI":"10.1210\/jc.2013-2674","article-title":"Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study","volume":"98","author":"Puurunen","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.fertnstert.2015.01.019_bib38","first-page":"905","article-title":"Effects of metformin plus rosuvastatin on hyperandrogenism in polycystic ovary syndrome patients with hyperlipidemia and impaired glucose tolerance","volume":"35","author":"Celik","year":"2012","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.fertnstert.2015.01.019_bib39","first-page":"1408","article-title":"PCOS","volume":"2009","author":"Cahill","year":"2009","journal-title":"Clin Evid (Online)"},{"key":"10.1016\/j.fertnstert.2015.01.019_bib40","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3109\/09513590.2012.754876","article-title":"Ovulatory effects of flutamide in the polycystic ovary syndrome","volume":"29","author":"Paradisi","year":"2013","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.fertnstert.2015.01.019_bib41","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/humupd\/dmi054","article-title":"Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in nonobese adolescents and women","volume":"12","author":"Ibanez","year":"2006","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.fertnstert.2015.01.019_bib42","doi-asserted-by":"crossref","first-page":"4646","DOI":"10.1210\/jc.2013-2374","article-title":"Adverse effects of the common treatments for polycystic ovary syndrome: a systematic review and meta-analaysis","volume":"98","author":"Domecq","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.fertnstert.2015.01.019_bib43","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1687-9856-2011-9","article-title":"State of the art review: emerging therapies: the use of insulin sensitizers in the treatment of adolescents with polycystic ovary syndrome (PCOS)","author":"Geller","year":"2011","journal-title":"Int J Pediatr Endocrinol"},{"key":"10.1016\/j.fertnstert.2015.01.019_bib44","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2147\/IJWH.S11304","article-title":"Treatment options for polycystic ovary syndrome","volume":"3","author":"Badawy","year":"2011","journal-title":"Int J Womens Health"},{"key":"10.1016\/j.fertnstert.2015.01.019_bib45","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1097\/AOG.0b013e3181bd12cb","article-title":"ACOG practice bulletin no. 108: Polycystic ovary syndrome","volume":"114","year":"2009","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.fertnstert.2015.01.019_bib46","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1530\/eje.0.1410361","article-title":"Comparison of finasteride versus flutamide in the treatment of hirsutism","volume":"141","author":"Falsetti","year":"1999","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.fertnstert.2015.01.019_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/CLEP.S37559","article-title":"Epidemiology, diagnosis and management of polycystic ovary syndrome","volume":"6","author":"Sirmans","year":"2013","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.fertnstert.2015.01.019_bib48","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0015-0282(16)56518-2","article-title":"Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial","volume":"61","author":"Cusan","year":"1994","journal-title":"Fertil Steril"},{"key":"10.1016\/j.fertnstert.2015.01.019_bib49","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1210\/jcem-66-1-208","article-title":"Side effects of spironolactone therapy in the hirsute woman","volume":"66","author":"Helfer","year":"1988","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Fertility and Sterility"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0015028215000667?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0015028215000667?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T08:16:57Z","timestamp":1758010617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0015028215000667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S0015028215000667"],"URL":"https:\/\/doi.org\/10.1016\/j.fertnstert.2015.01.019","relation":{},"ISSN":["0015-0282"],"issn-type":[{"value":"0015-0282","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Off-label drug use in the treatment of\u00a0polycystic ovary syndrome","name":"articletitle","label":"Article Title"},{"value":"Fertility and Sterility","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fertnstert.2015.01.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}